The US FDA has approved Libtayo®, the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma in the USA.
Browsing: Disease Area > Skin
NICE have approved dabrafenib plus trametinib for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults.
A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study.
Checkpoint inhibitors increase median survival to 12.4 months, and more than double percentage of patients who survive 4 years or longer.
Choosing when to stop immunotherapy is an extremely difficult decision process – in this blog piece melanoma survivor T.J. Sharpe shares his thoughts on the recent KEYNOTE-006 data.
Keep checking back throughout the conference, we will be updating this article with the biggest news headlines from the American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA).
Positive late-stage data has been announced from the KEYNOTE-054 trial, investigating KEYTRUDA® (pembrolizumab) in high-risk stage III melanoma patients.
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.